FORMULATIONS
| SR.NO | PRODUCT NAME | STRENGTH | DOSAGE |
|---|---|---|---|
| 1 | ANTI-CANCER | ||
| Bendamustine Hydrochloride Monohydrate ^ # | 100 mg/ml | Injectable | |
| Carmustine * | 100 mg/vial | Injectable | |
| Cyclophosphamide Monohydrate *#(sterile powder) | 0.5 gm/vial, 1 gm/vial, 2gm/vial | Injectable | |
| Melphalan Hydrochloride *# | 50 mg/vial | Injectable | |
|
2 |
RARE DRUGS | ||
| Carglumic Acid * | 200 mg | Tablet | |
| Fomepizole * | 1 gm/ml | Injectable | |
| Fomepizole Sulfate * | 5 mg/ml | Injectable | |
| Trientine Hydrochloride USP* | 250mg | Capsule | |
| 3 | PHOSPHATE BINDERS | ||
| Sevelamer Carbonate | 400 & 800 mg | Tablet | |
| Sevelamer Hydrochloride* | 400 & 800 mg | Tablet | |
| 4 | HAEMATOLOGICALS | ||
| Argatroban USP ^ # | 250 mg/2.5 ml | Injectable | |
| Iron Sucrose Complex USP * # | 2.5 ml & 5 ml | Injectable | |
| Phytonadione (Vitamin K1) * | 5 mg | Tablet | |
| Phytonadione (Vitamin K1) *# (Emulsion) | 10 mg/ml | Injectable | |
| 5 | CARDIOVASCULAR | ||
| Colesevelam Hydrochloride * # | 625 mg | Tablet | |
| Hydralazine Hydrochloride USP # | 20 mg/ml | Injectable | |
| Nicardipine Hydrochloride USP ^ # | 2.5 mg/ml | Injectable | |
| 6 | ANTI-RHEUMATIC | ||
| Penicillamine ^ | 250 mg | Capsule | |
| 7 | CNS | ||
| Fosaprepitant Dimeglumine * | 150 mg/vial | Injectable | |
| Benztropine Mesylate USP ^# | 2mg/ml | Injectable | |
| 8 | ANESTHETICS | ||
| Ropivacaine Hydrochloride # | 10 mg/ml (1.0%), 5 mg/ml (0.5%) | Injectable | |
| 9 | SMOKING DETTERENTS | ||
| Nicotine Polacrilex* | 2 mg & 4 mg | Lozenges |
NOTE:
- All products marked * are under exclusivity for BOTH, the US & Europe market.
- All products marked ^ are under exclusivity for the US market.
- All products marked # are under validation & will be available shortly for commercial supply.
Patented products are available for R&D purposes only as permitted under 35 U.S.C. Section 271 (e) (I).